These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 32837681)

  • 21. Cytochrome P450 research and
    Guengerich FP
    J Biol Chem; 2019 Feb; 294(5):1671-1680. PubMed ID: 29871932
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans.
    Danielson PB
    Curr Drug Metab; 2002 Dec; 3(6):561-97. PubMed ID: 12369887
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interactions of mammalian cytochrome P450, NADPH-cytochrome P450 reductase, and cytochrome b(5) enzymes.
    Shimada T; Mernaugh RL; Guengerich FP
    Arch Biochem Biophys; 2005 Mar; 435(1):207-16. PubMed ID: 15680923
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prediction of drug metabolism: the case of cytochrome P450 2D6.
    Vermeulen NP
    Curr Top Med Chem; 2003; 3(11):1227-39. PubMed ID: 12769702
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emerging roles for brain drug-metabolizing cytochrome P450 enzymes in neuropsychiatric conditions and responses to drugs.
    Toselli F; Dodd PR; Gillam EM
    Drug Metab Rev; 2016 Aug; 48(3):379-404. PubMed ID: 27498925
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury.
    Shimizu Y; Sasaki T; Yonekawa E; Yamazaki H; Ogura R; Watanabe M; Hosaka T; Shizu R; Takeshita JI; Yoshinari K
    J Toxicol Sci; 2021; 46(4):167-176. PubMed ID: 33814510
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [From the Viewpoint of Drug Metabolism Research].
    Nakajima M
    Yakugaku Zasshi; 2017; 137(6):697-705. PubMed ID: 28566576
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-P450 Drug-Metabolizing Enzymes: Contribution to Drug Disposition, Toxicity, and Development.
    Fukami T; Yokoi T; Nakajima M
    Annu Rev Pharmacol Toxicol; 2022 Jan; 62():405-425. PubMed ID: 34499522
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Toxicological significance of mechanism-based inactivation of cytochrome p450 enzymes by drugs.
    Masubuchi Y; Horie T
    Crit Rev Toxicol; 2007 Jun; 37(5):389-412. PubMed ID: 17612953
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolism and interactions of Ivermectin with human cytochrome P450 enzymes and drug transporters, possible adverse and toxic effects.
    Rendic SP
    Arch Toxicol; 2021 May; 95(5):1535-1546. PubMed ID: 33719007
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human cytochrome P450 enzymes 5-51 as targets of drugs and natural and environmental compounds: mechanisms, induction, and inhibition - toxic effects and benefits.
    Rendic SP; Peter Guengerich F
    Drug Metab Rev; 2018 Aug; 50(3):256-342. PubMed ID: 30717606
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical pharmacogenetics and potential application in personalized medicine.
    Zhou SF; Di YM; Chan E; Du YM; Chow VD; Xue CC; Lai X; Wang JC; Li CG; Tian M; Duan W
    Curr Drug Metab; 2008 Oct; 9(8):738-84. PubMed ID: 18855611
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Conventional and novel approaches in generating and characterization of reactive intermediates from drugs/drug candidates.
    Orhan H; Vermeulen NP
    Curr Drug Metab; 2011 May; 12(4):383-94. PubMed ID: 21395525
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modulation of cytochrome-P450 inhibition (CYP) in drug discovery: a medicinal chemistry perspective.
    Kumar S; Sharma R; Roychowdhury A
    Curr Med Chem; 2012; 19(21):3605-21. PubMed ID: 22680629
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytochrome P450 enzymes in drug metabolism and chemical toxicology: An introduction.
    Furge LL; Guengerich FP
    Biochem Mol Biol Educ; 2006 Mar; 34(2):66-74. PubMed ID: 21638641
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytochrome P450 networks in chemical space.
    Lee S; Kim D
    Arch Pharm Res; 2010 Sep; 33(9):1361-74. PubMed ID: 20945135
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New trends in cytochrome p450 research at the half-century mark.
    Guengerich FP
    J Biol Chem; 2013 Jun; 288(24):17063-4. PubMed ID: 23632015
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chimeric mice with humanized liver.
    Katoh M; Tateno C; Yoshizato K; Yokoi T
    Toxicology; 2008 Apr; 246(1):9-17. PubMed ID: 18248870
    [TBL] [Abstract][Full Text] [Related]  

  • 39. From electrochemistry to enzyme kinetics of cytochrome P450.
    Shumyantseva VV; Kuzikov AV; Masamrekh RA; Bulko TV; Archakov AI
    Biosens Bioelectron; 2018 Dec; 121():192-204. PubMed ID: 30218927
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution.
    Emoto C; Murayama N; Rostami-Hodjegan A; Yamazaki H
    Curr Drug Metab; 2010 Oct; 11(8):678-85. PubMed ID: 20973757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.